biotech / news / / Benzinga
FDA Panel Backs Truqap In Prostate Cancer.
The FDA panel endorsed Truqap with abiraterone for PTEN-deficient mHSPC based on CAPItello-281 data.
KEY POINTS
- Truqap combination improved median radiographic progression-free survival to 33.2 months versus 25.7 months.
- Grade 3 or higher adverse events were more frequent in the Truqap arm but manageable.
- The FDA panel rejected camizestrant for HR-positive, HER2-negative breast cancer despite strong progression risk reduction.
- A later pre-planned analysis showed camizestrant provided a significant PFS2 benefit of 25.7 months.
COMPANIES
Summarized by Newsio from Benzinga. How we summarize →